Strategic Cooperation | Sanyou Biopharmaceuticals signed a strategic cooperation agreement with Huadong Medicine with regard to innovative double antibody and ADC drugs.-Sanyou Biopharmaceuticals Co., Ltd.

Biological Drug R&D, Ask Sanyou Bio

Return News

Strategic Cooperation | Sanyou Biopharmaceuticals signed a strategic cooperation agreement with Huadong Medicine with regard to innovative double antibody and ADC drugs.

Time：2020.12.01 Author：Sanyou Bio From：Sanyou Bio

Sanyou Biopharmaceuticals announced that it had signed a strategic cooperation agreement with Huadong Medicine with regard to cooperative development of innovative double antibodies against high-quality targets and ADC molecules to accelerate the marketing of a new generation of anti-tumor drugs.

On November 20, 2020, Sanyou Biopharmaceuticals, a biotechnology company that focuses on the integrated solution for innovative antibody drug R&D, announced that it had signed a strategic cooperation agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963) (Huadong Medicine) with regard to cooperative development of innovative double antibodies against high-quality targets and ADC molecules to accelerate the marketing of a new generation of anti-tumor drugs.

With an independently integrated development platforms for high-quality antibody drugs and an internationally leading series of sub-trillion antibody libraries, Sanyou Biopharmaceuticals has the capability to efficiently construct and screen new double antibodies against specific targets and ADC molecules; Huadong Medicine possesses profound technical accumulation, clinical insight, and business integration ability in the field of anti-tumor and has the strength to transform innovative molecules into leading drugs and promote their rapid marketing.

This cooperation is an important layout of Huadong Medicine to accelerate the strategic transformation of innovative drugs, as well as a breakthrough to promote the strategy of innovative antibody drugs by Sanyou Biopharmaceuticals with leading pharmaceutical companies. Through long-term friendly cooperation, both parties hope to accelerate the marketing of innovative drugs and benefit patients around the world.

About Huadong Medicine

Founded in 1993 and ranked as top 10 in Fortune China in 2020, Huadong Medicine (SZ.000963),is a publicly-traded pharmaceutical company which integrates R&D, manufacturing, sales and business. With marketing channels in tens of thousands of large and medium-sized hospitals,Huadong Medicine has more than 10,000 employees in China, including more than 1,000 R&D personnel, covering all R&D links of drug discovery, preclinical study, clinical study, CMC and registration. Focusing on the innovation and transformation strategy, it is committed to building a deep R&D pipeline for innovative products of tumor, endocrine and autoimmune diseases with the help of R&D resources and management capabilities as well as rich partners with cutting-edge technical means.

Last

News Express | Sanyou Biopharmaceuticals and Minhang Development Zone signed contract on site in phase 4 activity of "Monthly Investment in Minhang".